All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

26

Reset

26 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • SEP-363856UlotarontPhase 37 trials

    Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder

  • NBI-1117568Phase 35 trials

    Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania

  • LB-102Phase 34 trials

    LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder

  • HS-10380Phase 33 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · SCHIZOPHRENIA 1 (Disorder)

  • SPG302TazbentetolPhase 33 trials

    Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis

  • OLZSAM, ALKS 3831Phase 32 trials

    Alkermes, Inc. · Bipolar I Disorder, Schizophrenia

  • B2227Phase 31 trial

    Bostal Drug Delivery Co., Ltd · Schizophrenia

  • ML-007C-MAPhase 24 trials

    MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia

  • ALTO-101Phase 21 trial

    Alto Neuroscience · Schizophrenia, Cognitive Impairment

  • BR5402APhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402A-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402BPhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402B-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402CPhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402C-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402DPhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402D-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • GXV813Phase 21 trial

    Novartis · Schizophrenia

  • KYN-5356Phase 21 trial

    Kynexis B.V. · Cognitive Impairment Associated With Schizophrenia (CIAS)

  • LY03020Phase 21 trial

    Luye Pharma Group Ltd. · Schizophrenia

  • NBI-1117570Phase 21 trial

    Neurocrine Biosciences · Schizophrenia

  • NS-136Phase 21 trial

    NeuShen Therapeutics · Schizophrenia(Acute)

  • RL-007InidascaminePhase 21 trial

    Recognify Life Sciences · Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia

  • SIPI6398Phase 21 trial

    Shanghai Zhongze Therapeutics Co., Ltd. · Schizophrenia Disorder

  • VV119Phase 21 trial

    Vigonvita Life Sciences · Schizophrenia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.